Advertisement

Clinical and Experimental Medicine

, Volume 19, Issue 3, pp 281–288 | Cite as

Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature

  • Maria Giulia TintiEmail author
  • Vincenzo Carnevale
  • Michele Inglese
  • Francesca Molinaro
  • Marco Bernal
  • Alberto Migliore
  • Angelo De Cata
Review Article
  • 107 Downloads

Abstract

Catastrophic antiphospholipid syndrome (CAPS) is a rare disorder, characterized by the development of multiple vascular thrombosis over a short period of time, in patients with persistently detectable antiphospholipid antibodies (aPLs). The vascular occlusions predominantly affect small vessels. The overall mortality is 36.9%, despite the recent progress in the therapeutic approach. It has been shown that aPLs are able to induce a hypercoagulability state through different mechanisms of action, including complement activation, which in turn plays a key role in the pathogenesis of some thrombotic microangiopathies. Consequently, complement inhibition may be proposed as a targeted intervention to effectively prevent the progression of the microthrombotic storm. The employment of the complement inhibitor eculizumab has been proposed in CAPS on the basis of occasional reports and expert opinion. We report the case of a 54-year-old woman with a CAPS refractory to conventional therapies, who was successfully treated with eculizumab. The administration of this anti-C5 monoclonal antibody aborted the acute progressive thrombotic events and prevented further clinical episodes of thrombosis in the following year. We also faced our case to a systematic literature review, by analyzing all reported cases of CAPS in which eculizumab was added to conventional therapy. Even if further investigation is needed, our results suggest that the inhibition of one mechanism of aPL-induced organ damage may be an add-on treatment for this condition.

Keywords

Eculizumab Catastrophic antiphospholipid syndrome Complement Thrombotic microangiopathy 

Notes

Funding

This research did not received specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from our patient.

References

  1. 1.
    Asherson R, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–4.CrossRefGoogle Scholar
  2. 2.
    Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103.CrossRefGoogle Scholar
  3. 3.
    Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19:508–12.Google Scholar
  4. 4.
    Espinosa G, Rodríguez-Pintó I, Cervera R. Catastrophic antiphospholipid syndrome: an update. Panminerva Med. 2017;59:254–68.Google Scholar
  5. 5.
    Cervera R, Tincani A. European Working Party on systemic lupus erythematosus and European Forum on Antiphospholipid Antibodies: two networks promoting European research on autoimmunity. Lupus. 2009;18:18863–8.Google Scholar
  6. 6.
    Cervera R, Rodriguez-Pinto I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun. 2018;92:1–11.CrossRefGoogle Scholar
  7. 7.
    Cervera R, Piette J-C, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.CrossRefGoogle Scholar
  8. 8.
    Cervera R, Font J, Gómez-Puerta J, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205–9.CrossRefGoogle Scholar
  9. 9.
    Cervera R, Rodríguez-Pintó I, Colafrancesco S, et al. 14th International congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev. 2014;13:699–707.CrossRefGoogle Scholar
  10. 10.
    Rodríguez-Pintó I, Espinosa G, Erkan D, Shoenfeld Y, Cervera R, CAPS Registry Project Group. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology. 2018;57:1264–70.CrossRefGoogle Scholar
  11. 11.
    Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010;10:74–9.CrossRefGoogle Scholar
  12. 12.
    Bayraktar UD, Erkan D, Bucciarelli S, Espinosa G, Asherson R, Catastrophic Antiphospholipid Syndrome Project Group. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol. 2007;34:346–52.Google Scholar
  13. 13.
    Espinosa G, Berman H, Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev. 2011;10:664–8.CrossRefGoogle Scholar
  14. 14.
    Asherson RA, Espinosa G, Menahem S, et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum. 2008;37:366–72.CrossRefGoogle Scholar
  15. 15.
    Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R. Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum. 2013;42:417–23.CrossRefGoogle Scholar
  16. 16.
    Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012;64:2719–23.CrossRefGoogle Scholar
  17. 17.
    Erkan D, Salmon JE. The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk J Haematol. 2016;5:1–7.Google Scholar
  18. 18.
    Barratt-Due A, Fløisand Y, Orrem HL, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. 2016;55:1337–9.CrossRefGoogle Scholar
  19. 19.
    Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine. 2014;93:e143.CrossRefGoogle Scholar
  20. 20.
    Kello N, LE Khoury, Marder G, Furie R, Zapantis E, Horowitz DL. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature. Semin Arthritis Rheum. 2018.  https://doi.org/10.1016/j.semarthrit.2018.11.005.Google Scholar
  21. 21.
    Lonze BE, Singer AL, Montgomery R. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362:1744–5.CrossRefGoogle Scholar
  22. 22.
    Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014;14:459–65.CrossRefGoogle Scholar
  23. 23.
    Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T. 36-Year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014;2014:704371.Google Scholar
  24. 24.
    Zikos TA, Sokolove J, Ahuja N, Berube C. Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol. 2015;6:311–3.CrossRefGoogle Scholar
  25. 25.
    Wig S, Chan M, Thachil J, Bruce I, Barnes T. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology. 2016;55:382–4.CrossRefGoogle Scholar
  26. 26.
    Guillot M, Rafat C, Buob D, et al. Eculizumab for catastrophic antiphospholipid syndrome—a case report and literature review. Rheumatology. 2018;57:2055–7.CrossRefGoogle Scholar
  27. 27.
    Tedesco F, Borghi MO, Gerosa M, et al. Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications. Front Immunol. 2018;9:1388.CrossRefGoogle Scholar
  28. 28.
    Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum. 2005;52:2120–4.CrossRefGoogle Scholar
  29. 29.
    Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol. 2007;196:1–5.CrossRefGoogle Scholar
  30. 30.
    Rodriguez-Pintó I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: the current management approach. Best Pract Res Clin Rheumatol. 2016;30:239–49.CrossRefGoogle Scholar
  31. 31.
    Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG. When to stop eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol. 2018;48:96–107.CrossRefGoogle Scholar
  32. 32.
    Merrill SA, Brittingham ZD, Yuan X, Moliterno AR, Sperati CJ, Brodsky RA. Eculizumab cessation in atypical hemolytic uremic syndrome. Blood. 2017;130:368–72.CrossRefGoogle Scholar
  33. 33.
    Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: state of the art. Mol Immunol. 2015;67:31–42.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Unit of Internal Medicine‘Casa Sollievo della Sofferenza’ Hospital, I.R.C.C.S.San Giovanni RotondoItaly
  2. 2.Department of Medical and Surgical SciencesUniversity of FoggiaFoggiaItaly
  3. 3.Unit of RheumatologySan Pietro Fatebenefratelli HospitalRomeItaly

Personalised recommendations